2026年8月27日 22:48 UTC / 路透社
%20vaccine%20at%20Skippack%20Pharmacy%20in%20Schwenksville,%20Pennsylvania,%20U.S.%20September%2011,%202025.%20REUTERS/Hannah%20Beier?auth=2d21a167a0887892888058505980318183373030718771207373031071371717&width=1200&quality=80)
路透社/汉娜·拜尔 授权许可购买
拜恩泰科公司
莫德纳公司
诺瓦瓦克斯公司
查看更多企业
8月27日（路透社）——相关企业周四表示，美国食品药品监督管理局已批准莫德纳、诺瓦瓦克斯-赛诺菲以及辉瑞-拜恩泰科的更新版新冠疫苗。此前该机构的咨询小组建议，此次更新的疫苗应针对当前主流的XFG变异株。
订阅屡获殊荣的路透社健康简报《路透健康周刊》，及时了解最新医学突破与医疗趋势。点击此处注册
- 美国已批准四款新冠疫苗上市：莫德纳的mNEXSPIKE和Spikevax、辉瑞-拜恩泰科的Comirnaty——以上三款均为mRNA疫苗——以及诺瓦瓦克斯-赛诺菲的蛋白亚单位疫苗，该类疫苗的生产周期更长。
- 所有疫苗生产商此前均表示，可按时完成更新版疫苗的生产，以赶上2026-2027免疫接种季。
- 今年5月，该咨询委员会的9名专家中有8人投票赞成，将2026-2027接种季的新冠疫苗靶点定为XFG变异株。
- 2025-2026接种季，美国FDA曾建议新冠疫苗针对LP.8.1变异株——JN.1毒株的一个亚分支。
- 根据美国疾病控制与预防中心的新冠疫情数据面板，由于病毒测序提交量较低，目前暂无最新的毒株相关数据。
克里斯蒂·桑托什 班加罗尔报道；乔伊吉特·达斯 编辑
我们的报道准则：汤森路透信托原则
US FDA approves updated COVID vaccines for 2026-27 season
August 27, 2026 9:48 PM UTC / Reuters
A child receives a dose of the Moderna coronavirus disease (COVID-19) vaccine at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S. September 11, 2025. REUTERS/Hannah Beier Purchase Licensing Rights
BioNTech SE
Moderna Inc
Novavax, Inc.
Show more companies
Aug 27 (Reuters) – The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech’s updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG variant.
Keep up with the latest medical breakthroughs and healthcare trends with the award-winning Reuters Health Rounds newsletter. Sign up here.
- Four COVID shots had been approved for use in the United States: Moderna’s mNEXSPIKE and Spikevax, Pfizer-BioNTech’s , Comirnaty — all three mRNA-based vaccines — and Novavax-Sanofi’s , protein-based shot that takes longer to manufacture.
- All manufacturers previously said they could make the updated shot in time for the 2026-27 immunization season.
- In May, eight of the committee’s nine experts voted in favor of targeting the XFG variant for the 2026-27 campaign.
- For the 2025-26 season, the FDA had recommended COVID shots target LP.8.1 — a subvariant of the JN.1 strain.
- According to the Centers for Disease Control and Prevention’s COVID dashboard, new data on strains is currently unavailable due to low sequencing submissions.
Reporting by Christy Santhosh in Bengaluru; Editing by Joyjeet Das
Our Standards: The Thomson Reuters Trust Principles.
发表回复